Details of the Drug

General Information of Drug (ID: DMYEB5F)

Drug Name
CC-115
Synonyms CC-115 (hydrochloride); CC-115 hydrochloride; 1300118-55-1; SCHEMBL1767621; BCP20709; HY-16962A; AKOS030526389
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 1 [1]
Non-hodgkin lymphoma 2B33.5 Phase 1 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C16H16N8O
Canonical SMILES
CCN1C(=O)CNC2=NC=C(N=C21)C3=C(N=C(C=C3)C4=NC=NN4)C
InChI
InChI=1S/C16H16N8O/c1-3-24-13(25)7-18-15-16(24)22-12(6-17-15)10-4-5-11(21-9(10)2)14-19-8-20-23-14/h4-6,8H,3,7H2,1-2H3,(H,17,18)(H,19,20,23)
InChIKey
GMYLVKUGJMYTFB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
58298318
ChEBI ID
CHEMBL3586573
CAS Number
1228013-15-7
UNII
FII75TFH5L
DrugBank ID
DB12740
TTD ID
D0O1IM
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 ClinicalTrials.gov (NCT01353625) Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.. U.S. National Institutes of Health.